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Effect of selenium supplementation on musculoskeletal 
health in older women: a randomised, double-blind, 
placebo-controlled trial 
Jennifer S Walsh, Richard M Jacques, Lutz Schomburg, Tom R Hill, John C Mathers, Graham R Williams, Richard Eastell
Summary
Background Observational and preclinical studies show associations between selenium status, bone health, and 
physical function. Most adults in Europe have serum selenium below the optimum range. We hypothesised that 
selenium supplementation could reduce pro-resorptive actions of reactive oxygen species on osteoclasts and improve 
physical function.
Methods We completed a 6-month randomised, double-blind, placebo-controlled trial. We recruited postmenopausal 
women older than 55 years with osteopenia or osteoporosis at the Northern General Hospital, Sheffield, UK. 
Participants were randomly assigned 1:1:1 to receive selenite 200 μg, 50 μg, or placebo orally once per day. Medication 
was supplied to the site blinded and numbered by a block randomisation sequence with a block size of 18, and 
participants were allocated medication in numerical order. All participants and study team were masked to treatment 
allocation. The primary endpoint was urine N-terminal cross-linking telopeptide of type I collagen (NTx, expressed as 
ratio to creatinine) at 26 weeks. Analysis included all randomly assigned participants who completed follow-up. 
Groups were compared with analysis of covariance with Hochberg testing. Secondary endpoints were other 
biochemical markers of bone turnover, bone mineral density, short physical performance battery, and grip strength. 
Mechanistic endpoints were glutathione peroxidase, highly sensitive C-reactive protein, and interleukin-6. This trial 
is registered with EU clinical trials, EudraCT 2016-002964-15, and ClinicalTrials.gov, NCT02832648, and is complete.
Findings 120 participants were recruited between Jan 23, 2017, and April 11, 2018, and randomly assigned to selenite 
200 μg, 50 μg, or placebo (n=40 per group). 115 (96%) of 120 participants completed follow-up and were included in 
the primary analysis (200 μg [n=39], 50 μg [n=39], placebo [n=37]). Median follow-up was 25·0 weeks (IQR 24·7–26·0). 
In the 200 μg group, mean serum selenium increased from 78·8 (95% CI 73·5–84·2) to 105·7 μg/L (99·5–111·9). 
Urine NTx to creatinine ratio (nmol bone collagen equivalent:mmol creatinine) did not differ significantly between 
treatment groups at 26 weeks: 40·5 (95% CI 34·9–47·0) for placebo, 43·4 (37·4–50·5) for 50 μg, and 42·2 (37·5–47·6) 
for 200 μg. None of the secondary or mechanistic endpoint measurements differed between treatment groups at 
26 weeks. Seven (6%) of 120 participants were withdrawn from treatment at week 13 due to abnormal thyroid-
stimulating hormone concentrations (one in the 200 μg group, three in the 50 μg group, and three in the placebo 
group) and abnormal blood glucose (one in the 50 µg group). There were three serious adverse events: a non-ST 
elevation myocardial infarction at week 18 (in the 50 μg group), a diagnosis of bowel cancer after routine population 
screening at week 2 (in the placebo group), and a pulmonary embolus due to metastatic bowel cancer at week 4 (in the 
200 μg group). All severe adverse events were judged by the principal investigator as unrelated to trial medication. 
Interpretation Selenium supplementation at these doses does not affect musculoskeletal health in postmenopausal 
women.
Funding UK National Institute for Health Research Efficacy and Mechanism Evaluation programme. 
Copyright © 2021 The Authors. Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. 
Introduction 
One in two women and one in five men older than 
50 years in the UK will have a fragility fracture, defined 
as a fracture that results from a fall from standing height 
or less. About 30% of women older than 65 years are 
osteopenic and at risk of developing osteoporosis 
and fractures. More than half of all fractures in 
postmenopausal women occur in women with 
osteopenia. Women with osteopenia are generally not 
given osteoporosis treatment because of the individual 
risk to benefit ratio. Previously, these women would have 
been offered hormone replacement therapy for bone 
protection, but adverse effects of this therapy have 
limited its use. Bisphosphonates are the mainstay of 
osteoporosis treatment for women at higher risk, but use 
of these medications has declined due to physician and 
patient wariness of adverse events.1 Calcium and 
vitamin D supplements are generally recommended for 
osteopenic adults, but the bone density benefits are 
small. Therefore, there is a need for an effective, safe, 
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well tolerated, inexpensive, and widely applicable 
treatment option for osteopenic women.
High bone turnover is the principal mechanism of 
osteoporotic bone loss, and inflammatory cytokines and 
reactive oxygen species are potent stimuli for bone 
resorption.2,3 An increase in reactive oxygen species has 
been proposed as a key mechanism by which sex 
hormone deficiency causes age-related bone loss through 
the RANK pathway.4 
In 1144 postmenopausal women older than 55 years 
from the UK, France, and Germany, higher serum 
selenium or selenoprotein P was associated with higher 
bone mineral density (BMD) of the lumbar spine and 
total hip, and lower biochemical markers of bone 
turnover.5 Serum selenium concentration was also 
associated with balance and grip strength. Lower serum 
selenium was associated with higher free T4 and T3, but 
the associations of selenium with bone measures were 
independent of thyroid hormones. 
Selenoproteins contribute to anti-inflammatory and 
antioxidative pathways, and increased selenoprotein 
expression is associated with reduced interleukin (IL)-6 
and reactive oxygen species,6,7 and so it is plausible 
that selenium could affect bone metabolism directly. 
Selenoproteins are expressed in osteoblasts and osteo-
clasts, and are found in the bone micro environment.8,9 
Through antioxidative catalysis and reducing reactive 
oxygen species, selenium could directly antagonise a key 
cellular mechanism in the pathogenesis of post meno-
pausal osteoporosis.
There is animal evidence to support the hypothesis that 
selenium has a role in bone biology and decreases bone 
turnover. Selenium deficient rodents have abnormal bone 
growth, poorer bone microarchitecture, higher bone 
resorption markers, and higher inflammatory markers 
than selenium replete controls.10,11
Endemic selenium deficiency in humans has been 
associated with the osteoarthropathy Kashin-Beck 
disease.12 Selenium status has also been associated with 
BMD in men in the Netherlands,13 and higher selenium 
intake was associated with lower hip fracture risk in 
adults older than 50 years in the USA.14
Selenium is obtained from dietary intake; the main 
sources of selenium in the UK are bread, cereals, seafood, 
and meat. The main determinant of food selenium 
content is soil selenium availability. The recommended 
adequate intake for adults older than 50 years in the UK is 
75 μg for men and 60 μg for women, daily, but the mean 
intake is only 40 μg daily.15 The decreasing intake in the 
UK is due to a shift in the source of flour for bread-
making from North America (which contains more 
selenium) to Europe, changes in fertiliser practice, and 
reduced industrial emissions.16 
Studies of all-cause mortality suggest that the optimum 
range of serum selenium for human health is 
approximately 120–150 μg/L. Most adults in the UK have 
serum selenium between 80 and 100 μg/L.15
Several other age-related disorders are linked to 
inadequate selenium status, including cardiovascular 
disease, poor cognitive function, and reduced muscle 
strength.17,18 Selenium supplementation (200 μg daily as 
selenised yeast) with enzyme Q10 reduced cardiovascular 
mortality and markers of inflammation and increased 
IGF-1 in Swedish adults older than 70 years.19,20 In the 
Nutritional Prevention of Cancer trial, selenium 
supplementation (also 200 μg daily as selenised yeast) 
reduced all-cancer risk in people with lower baseline 
serum selenium21 and meta-analyses generally find a 
beneficial effect of selenium on cancer risk.15 
Possible adverse effects of selenium supplementation 
include increased risk of type 2 diabetes. However, this 
was not seen when the large randomised supplementation 
studies were systematically evaluated by meta-analysis.22
We hypothesised that in a relatively selenium deficient 
population such as that in the UK, selenium supple-
mentation would decrease bone turnover by increasing 
selenoprotein expression and activity, reducing osteoclast 
activity, and might improve muscle function. In the 
longer term, both of these actions could reduce fracture 
risk.
Research in context 
Evidence before this study 
We searched PubMed and Google Scholar. Search terms were 
“selenium”, “bone”, “osteoporosis”, “fracture”, “physical 
function”, “muscle”, and “mortality”. The search was limited to 
English language publications and was not limited by 
publication date. Preclinical, epidemiological, and observational 
studies suggest a role for selenium in bone and muscle health, 
and analysis of the Osteoporosis and Ultrasound (OPUS) study 
data by some of the authors of this paper confirmed a 
relationship between serum selenium, bone turnover markers, 
and bone mineral density. Clinical trials have shown efficacy of 
selenium supplements for cancer prevention and Graves’ eye 
disease.
Added value of this study 
This study is the first randomised, double-blind placebo-
controlled trial of selenium for musculoskeletal health. 
Supplemental sodium selenite (200 μg or 50 μg daily) for 
6 months had no effect on biochemical markers of bone 
turnover or physical function tests.
Implications of all the available evidence 
Selenium supplementation at these doses does not affect bone 
health or physical function in postmenopausal women. 
Observed associations between selenium status and bone 
health could be influenced by other factors. A single nutrient 
supplementation approach with selenium might be ineffective 
in this context. 
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The objectives of the study were to determine if 
selenium supplementation in postmenopausal women 
with osteopenia decreases bone turnover, improves 
physical function score and grip strength, is safe 
(particularly for thyroid function and diabetes), increases 
biomarkers of selenium status, and decreases markers of 
oxidative stress and inflammation.
Methods
Study design and participants
We conducted a randomised, double-blind, placebo-
controlled study of 6 months of selenium supple-
mentation in postmenopausal women with osteopenia or 
osteoporosis. This was a single centre study, at the 
Northern General Hospital, Sheffield, UK. 
Participants were recruited from a database of 
volunteers, by poster and email advertising, and from 
patients attending the metabolic bone centre for bone 
densitometry. Inclusion criteria were: age older than 
55 years, at least 5 years since last menstrual period, 
osteopenia or osteoporosis (dual-energy x-ray absorpti-
ometry BMD lowest T-score between –1·0 and –3·0 at 
lumbar spine or total hip), and willing and able to give 
informed consent. Exclusion criteria were: diabetes, 
thyroid dysfunction, any conditions known to affect bone 
metabolism (such as inflammatory disease, parathyroid 
disease, malabsorption, high alcohol intake, and 
prolonged immobility), fracture or orthopaedic surgery 
in the last year, osteoporosis treatment or drugs known 
to affect bone metabolism in the last year, selenium 
supplements in the last 60 days, or previous adverse 
reaction to selenium or any of the selenite or placebo 
excipients. Women taking calcium and vitamin D 
supplements were not excluded if they had been taking 
the calcium and vitamin D for at least 60 days and 
planned to continue throughout the trial. We did not set 
inclusion and exclusion criteria based on serum 
selenium status, so that the results of this study could be 
generalised into practice. However, we specified that only 
women with baseline serum selenium of less than 
120 μg/L would be included in the primary analysis. 
All participants gave written informed consent and the 
study was done in accordance with the Declaration of 
Helsinki. The study was approved by Yorkshire and the 
Humber Research Ethics Committee (REC reference 16/
YH/0393; appendix pp 1, 9).
Randomisation and masking
Participants were randomly assigned 1:1:1 to either placebo 
or two different doses of selenium supple mentation. 
Sharp Clinical Services (Crickhowell, UK) generated a 
block randomisation sequence with a block size of 18 and 
no stratification. Medication containers were supplied to 
the site pharmacy blinded and numbered according to the 
randomisation sequence. Participants were allocated 
medication in numerical order. An emergency code break 
was held in the site pharmacy but was not accessed by the 
study team during the trial. JSW enrolled all participants. 
All participants and study team were blind to treatment 
allocation until after database lock. The selenite tablets 
were over-encapsulated and a matching placebo was also 
manufactured by Sharp Clinical Services.
Procedures
The interventions were sodium selenite tablets 50 μg or 
200 μg (Selenase, Biosyn, Fellbach, Germany) or placebo 
orally, once a day. We chose a daily dose of 200 μg because 
this dose has previously been shown to be safe and 
have clinically significant effects in the Nutritional 
Prevention of Cancer trial21 and in treatment of Graves’ 
ophthalmopathy.23 We estimated that this dose would 
increase serum selenium by approx imately 60 μg/L.24 The 
daily dose of 50 μg was included to assess dose response; 
if 50 μg and 200 μg had similar effects, we could 
recommend the 50 μg dose for clinical use, at lower cost 
and lower risk of adverse effects.
All participants were given a single oral dose of 
100 000 IU colecalciferol at screening, to ensure they 
were vitamin D sufficient at the start of trial treatment.
Participants attended for four visits: screening, baseline 
with randomisation, 13 weeks, and 26 weeks. They 
were contacted by telephone at 6 weeks, 19 weeks, and 
30 weeks. Height, weight, pulse, blood pressure, grip 
strength, short physical performance battery, and blood 
and urine tests were taken at baseline, 13 weeks, and 
26 weeks. Diet diaries and dual-energy x-ray absorptiometry 
BMD were done at screening and 26 weeks. Participants 
were withdrawn from treatment if they had abnormal 
concentrations of thyroid-stimulating hormone, glycated 
haemoglobin, or blood glucose at 13 weeks, or if they had 
serious adverse events judged to be due to the study 
medication, but they were asked to continue in  follow-up 
for the primary analysis. Participants were only removed 
from the trial if they withdrew consent. 
Outcomes
The primary endpoint was between-group difference in 
the ratio of urine N-terminal cross-linking telopeptide of 
type I collagen (NTx) to creatinine at 26 weeks. Bone 
turnover markers change much more rapidly than BMD, 
so can determine more quickly and cost-effectively if an 
intervention is likely to work. We chose NTx because the 
relationship between change in NTx and change in 
fracture risk is known. With bisphosphonate treatment,25 
a 30% decrease in NTx is associated with a 40% reduction 
in spine fracture, and 66% of the vertebral fracture risk 
reduction at 3 years is explained by change in NTx. Also, 
NTx was the marker most strongly related to selenium 
status in the previous observational study.5
The secondary endpoints were: serum selenium and 
selenoprotein P; other bone turnover markers (pro collagen 
type I N propeptide [PINP], osteocalcin, C-terminal cross-
linking telopeptide of type I collagen [CTx]), BMD of the 
lumbar spine and total hip by dual-energy x-ray 
See Online for appendix
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absorptiometry, muscle function (short physical 
performance battery and hand grip strength); antioxidant 
and inflammatory markers (glutathione peroxidase activity 
[a selenium-containing antioxidant that is increased in 
postmenopausal women with osteopenia],26 IL-6, and 
highly sensitive C-reactive protein). 
Blood samples for biochemical measurements were 
taken fasted in the morning. Serum samples were obtained 
in serum separation tubes, allowed to clot for 30 min, then 
centrifuged at 2500 rpm for 10 min and separated into 
aliquots. Urine samples were obtained as triplicate 
samples from fasted second morning voids on three days 
immediately before the study visit and kept refrigerated 
until the study visit. Equal volume aliquots from the urine 
samples were pooled into a single sample, then the pooled 
sample was separated into aliquots. Samples were frozen 
at –80°C and analysed in batches at the end of the study.
Urine NTx was measured by automated immunoassay 
(Vitros ECiQ, Ortho Clincal Diagnostics, High Wycombe, 
UK) at PathLab London (interassay coefficient of varia bility 
[CV] 6%). NTx was expressed as a ratio to urinary creatinine 
concentration measured by the dry slide method (Vitros 
250, Ortho Clinical Diagnostics, inter assay CV 3%). CTx, 
osteocalcin, PINP, and 25-hydroxyvitamin D were measured 
by automated immunoassay (IDS-iSYS, Immunodiagnostic 
Systems, Boldon, UK), by the University of Sheffield 
Academic Unit of Bone Metabolism. The interassay CVs are 
6·5, 5·0, 7·2, and 6·7%, respectively. Highly sensitive 
C-reactive protein and IL-6 were measured by automated 
immunoassay by the Sheffield Teaching Hospitals Clinical 
Immunology laboratory. Serum selenium was measured by 
x-ray fluorescence spectroscopy (S4 T-STAR, Bruker 
Nano Analytics, Berlin, Germany), selenoprotein P was 
measured by a validated immuno assay (selenOtest, 
selenOmed, Berlin, Germany), and glutathione peroxidase 
was measured by enzyme analysis using tButyl-OOH as 
substrate at the Institute for Experimental Endocrinology, 
Charité–University Medical School Berlin, Germany. 
Height and weight were measured with an electric 
scale and stadiometer to the nearest 0·1 cm and 0·1 kg. 
Pulse and blood pressure were measured with an auto-
mated sphygmomanometer (Dinamap, GE Healthcare, 
Chalfont St Giles, UK). Grip strength was assessed 
using a digital hand dynamometer (Saehan Corporation, 
Masan, South Korea). Three measure ments were taken 
for each hand and the best value used for analysis. Short 
physical performance battery score was calculated from 
a chair stand, tandem balance, and narrow walk test. 
BMD was assessed by dual-energy x-ray absorptiometry 
of the spine and hip (Discovery, Hologic, Manchester, 
UK) at baseline and at 26 weeks according to standard 
scanning protocols, by specialist scan technicians in the 
Sheffield Clinical Research Facility, UK.
Dietary selenium and other nutrient intake were 
assessed with 7-day diet diaries. The purpose of the food 
diaries was to describe participants’ habitual dietary 
intake of selenium and nutrients, which influence bone 
turnover. The diaries were analysed using DIETQ 
(Tinuviel Software, Warrington, UK) supervised by a 
nutritionist with experience in clinical research.
Safety assessments for diabetes and thyroid function 
were made at screening, baseline, 13 weeks, and 
26 weeks. The measurements were made in real time by 
Sheffield Teaching Hospitals pathology laboratories. 
Adverse events (including questioning for possible 
symptoms of selenium toxicity) were collected from the 
time of consent, at study visits, and during telephone 
contact throughout the treatment period and 4 weeks 
after the end of the treatment.
Statistical analysis
We hypothesised that selenium supplementation would 
decrease bone turnover and improve physical function.
The study had 90% power to detect a 20% between-
group difference at the 2·5% (two-sided) level 
(approximately 10 nmol bone collagen equivalent:mmol 
creatinine) in NTx to creatinine ratio at 26 weeks. A 20% 
decrease in NTx (about 1 SD decrease) with 
bisphosphonate treat ment is associated with a 30% 
decrease in incident vertebral fracture.27 We set 20% as a 
plausible effect size, based on estimated change in serum 
selenium and the regression coefficient of serum 
selenium and NTx to creatinine ratio in our previous 
study. We did not expect as large a change in bone 
turnover as a potent antiresorptive drug such as a 
bisphosphonate, but perhaps similar to a weaker anti-
resorptive such as a selective oestrogen receptor 
modulator. In a study of 6 months’ treatment with 
lasofoxifene in 51 postmenopausal women,28 NTx to 
creatinine ratio decreased by 29%. We also used this 
study to estimate the SD (12·5) and the correlation 
between NTx to creatinine ratio at baseline and at 
6 months (0·7). The primary analysis was analysis of 
covariance, and 21 patients per group were required.29 To 
allow for dropout, group imbalance, participants with 
baseline serum selenium of more than 120 μg/L, and the 
secondary endpoint analyses, we recruited 40 patients per 
group. 
We included an interim analysis of baseline serum 
selenium after the first 40 participants were recruited, 
with a plan to increase the sample size to ensure 
120 participants with baseline serum selenium of less 
than 120 μg/L for inclusion in the primary analysis. The 
only data reviewed were blinded baseline serum 
selenium concentrations. All the first 40 participants had 
baseline serum selenium of less than 120 μg/L, so 
we maintained the original recruitment target of 
120 participants. We did a secondary analysis of all 
partici pants to determine whether baseline serum 
selenium was a determinant of bone turnover response.
A detailed statistical analysis plan was developed and 
approved by the trial steering committee before locking 
the trial database. We did an intention-to-treat analysis (all 
randomised participants) and per-protocol analysis. The 
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per-protocol analysis included completing participants 
who took at least 75% of the study drug, assessed by 
reported missed doses and returned tablet count. 
Baseline data were assessed for comparability between 
the treatment groups. Normality of distribution of variables 
was assessed from either the raw data or the residuals 
from the model using a density plot or histogram.
Primary endpoint analysis was the between-group 
difference in urine NTx to creatinine ratio at 26 weeks. 
Analysis of covariance was used with 26-week NTx to 
creatinine measurement as the dependent outcome 
variable and treatment group and baseline NTx to 
creatinine measurement as the independent variables. If 
the residuals from the model were not normally 
distributed, the values would be log transformed and the 
treatment group differences back transformed to be 
presented as a ratio. 
The statistical analysis plan prespecified a Hochberg 
testing procedure30 for the primary endpoint which 
allows for comparison of the three treatment arms while 
maintaining the overall type I error rate at 5%. Significance 
would be declared for the comparison of placebo to 
selenium if, and only if, both selenium doses were 
significant at the 5% level or if either comparison was 
significant at 2·5%. If and only if significance was 
declared for both selenium doses, a comparison would 
be made between the doses. The comparison of 200 μg 
selenium versus 50 μg selenium would be made at the 
5% level of significance. 
We examined the effect of baseline selenium concen-
trations on the NTx to creatinine ratio response to 
selenium supplementation by fitting a linear model with 
NTx to creatinine ratio at follow-up as the dependent 
variable and baseline selenium, baseline NTx to 
creatinine ratio, and dose as independent variables. 
The statistical analysis plan prespecified a multiple 
imputation strategy for the primary endpoint with 
20 imputations using baseline and week 13 
measurements of NTx to creatinine ratio, age of patient, 
and treatment allocation to replace missing data. The 
plan specified that additional variables associated with 
missing data would also be included in the multiple 
imputation model to make the missing at random 
assumption as plausible as possible. The nature of 
Figure: Trial profile 
The number of participants included in the per-protocol analysis differs from the  per-protocol NTx results table (appendix p 2) due to missing NTx measurements. 
AE=adverse event. BMD=bone mineral density. NTx=N-terminal cross-linking telopeptide of type I collagen. TSH=thyroid-stimulating hormone.  
187 consented and screened
120 randomly assigned
67 not randomly assigned
 48 BMD too high or low 
 14 abnormal blood sugar or TSH
 3 withdrew after screening
 2 other
480 approached
 75 not interested
 198 no reply




37 included in primary analysis
26 included in per-protocol analysis
1 stopped treatment due to AE
3 stopped treatment due to TSH
7 compliance <75%
40 assigned selenite 50 μg
39 included in primary analysis
31 included in per-protocol analysis
1 stopped treatment due to AE
3 stopped treatment due to TSH




40 assigned selenite 200 μg
39 included in primary analysis
34 included in per-protocol analysis






 1161 BMD too high or low
 690 disease or drug affecting bone
 207 diabetes or thyroid dysfunction
 59 recent fracture
 16 frailty or dementia 
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missingness and other baseline variables was explored in 
relation to missing data on the primary endpoint using 
univariable logistic regression models. The only baseline 
variable predictive of missingness was body-mass index. 
The final multiple imputation model therefore used 
baseline and week 13 measurements of NTx to creatinine 
ratio, age of patient, body-mass index of patient at 
baseline, and treatment allocation. Seven of the week 26 
NTx to creatinine ratio values and two of the baseline NTx 
to creatinine ratio values were missing and were replaced 
by imputation. The results using the imputation model 
did not differ from the primary analysis.
Analysis of secondary endpoints included urine NTx to 
creatinine ratio at 13 weeks and BMD by dual-energy 
x-ray absorptiometry at 26 weeks, which were analysed as 
described for the primary endpoint. All other secondary 
endpoint measurements at 13 and 26 weeks were 
compared between treatment groups using linear mixed 
models with a random intercept to allow for multiple 
measurements on individuals. 
The models included fixed factors for treatment group 
and post randomisation time, and a covariate for the 
baseline measurement of the outcome. To determine if 
the effect of treatment changed with time, an interaction 
between treatment group and time was tested. If this 
interaction was not statistically significant, it was 
removed from the model and the overall treatment 
difference was reported. If there was a significant dif-
ference between treatment groups, pairwise comparisons 
were made between each treatment group and placebo 
and then the two doses against each other. In the original 
protocol we planned to measure hydroperoxidases as a 
mechanistic variable, but we did not make these 
measurements because there was no suitable assay 
available when the trial was completed.
This study is registered with EU clinical trials, EudraCT 
2016-002964-15, and ClinicalTrials.gov NCT02832648. 
The trial was supervised by a Trial Steering Committee 
and a Data Monitoring Committee.
Role of the funding source
The National Institute for Health Research (NIHR) had 
some initial input to the study design through the grant 
application review process. The NIHR had no role in data 
collection, data analysis, or data interpretation. The full 
study report was subject to independent review through 
standard NIHR processes.  
Results
We recruited 120 women between Jan 23, 2017, and 
April 11, 2018. The last participant completed follow-up 
on Nov 6, 2018. Median follow-up was 25·0 weeks 
(IQR 24·7–26·0). 115 (96%) of 120 participants completed 
follow-up and were included in the primary analysis 
(figure). Baseline characteristics are shown in table 1. 
The groups were generally well balanced, and the 
mean baseline serum selenium was 79·4 μg/L 
(range 35·1–116·5). As all participants had baseline 
serum selenium below 120 μg/L, all were included in the 
primary analysis. Weight and body-mass index did not 
change over 26 weeks in any of the groups (data not 
shown).
The sample size calculation assumed a correlation 
between baseline and week 26 NTx to creatinine ratio 
measurement of 0·7. In the primary analysis population, 
the Pearson correlation between baseline and week 26 
NTx to creatinine ratio was 0·62 (95% CI 0·49–0·73). 
The residuals from the model were not normally 
distributed so the NTx to creatinine ratio was log-
transformed and the treatment group differences were 
back transformed to be presented as a ratio.
The primary endpoint (urine NTx to creatinine ratio) did 
not differ between treatment groups after 26 weeks or 
13 weeks (table 2). 86 (72%) of 120 participants were 
included in the per-protocol analysis, and NTx to creatinine 
Placebo  
(n=37)
Selenite 50 μg 
(n=39)
Selenite 200 μg 
(n=39)
Age, years
n 37 39 39
Mean (SD) 66·6 (6·0) 66·7 (6·1) 64·5 (6·1)
Height, cm
n 37 39 39
Mean (SD) 160·6 (5·7) 162·0 (6·4) 161·5 (7·9)
Weight, kg
n 37 39 39
Mean (SD) 65·7 (11·2) 65·5 (9·2) 66·9 (10·8)
Body-mass index, kg/m²
n 37 39 39
Mean (SD) 25·6 (4·8) 25·0 (3·7) 25·7 (3·7)
Serum selenium, μg/L
n 37 38 39
Mean (SD) 80·2 (14·2) 79·3 (15·6) 78·8 (16·5)
Serum selenoprotein P, mg/L
n 37 38 39
Mean (SD) 5·22 (1·45) 5·21 (1·47) 5·15 (1·37)
Lumbar spine bone mineral density T–score
n 35 38 37
Mean (SD) –1·7 (0·9) –1·8 (1·0) –1·8 (0·6)
Total hip bone mineral density T–score
n 35 39 39
Mean (SD) –1·3 (0·7) –1·2 (0·7) –0·9 (0·6)
Urine NTx to creatinine ratio, nmol bone collagen equivalent:mmol 
creatinine
n 37 37 39
Median (IQR) 37·5 (29·7 to 
49·1)
38·2 (33·7 to 
49·7)
42·0 (35·0 to 
49·5)
Serum 25-hydroxyvitamin D, ng/ml
n 37 38 39
Mean (SD) 37·8 (10·8) 39·5 (12·1) 37·7 (12·7)
NTx=N-terminal cross-linking telopeptide of type I collagen.
Table 1: Baseline participant characteristics by treatment group
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ratio in this group did not differ between treatment groups 
after 26 weeks or 13 weeks (appendix p 2).
Mean serum selenium and selenoprotein P increased 
from baseline to 26 weeks in the treatment groups and 
there was no change in the placebo group (table 3 and 
appendix p 3). 
A linear regression model was fitted with log (week 26 
NTx to creatinine ratio) as the dependent variable and 
log (baseline NTx to creatinine ratio), baseline selenium, 
and treatment group as independent variables. The 
inter action between treatment group and baseline 
selenium was not statistically significant (p=0·47) 
suggesting that treatment group did not modify the 
relationship between baseline selenium and 26-week 
NTx to creatinine ratio. 
There were no differences between treatment groups 
in any of the other biochemical markers of bone turnover 
(PINP, CTx, or osteocalcin) at 26 weeks or 13 weeks 
(table 2). There were small statistically significant, but 
not clinically relevant, differences in lumbar spine BMD 
T-score at 26 weeks between the 50 μg group and placebo, 
and between the 50 μg group and 200 μg group. Total 
hip BMD did not differ between treatment groups at 
26 weeks (appendix p 4).
There was a statistically significant but small difference 
in short physical performance battery score in the 50 μg 
group compared with placebo at 26 weeks, but no 
difference between the 200 μg group and placebo. Grip 
strength did not differ between treatment groups (table 4).
Glutathione peroxidase activity and highly sensitive 
C-reactive protein did not differ between treatment 
groups at 13 or 26 weeks (appendix p 5). Most IL-6 
measurements did not reach the limit of detection of 
1·6 ng/L (74 of 110 at baseline, 71 of 110 at week 13, and 74 
of 108 at week 26), so no further analysis was done on the 
IL-6 measurements.
Placebo Selenite 50 μg Selenite 200 μg Selenite 50 μg vs placebo Selenite 200 μg vs placebo Selenite 200 μg vs 50 μg
n Mean n Mean n Mean Ratio p value Ratio p value Ratio p value
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Data are n, mean (95% CI), ratio of means (95% CI), or p value. All urine NTx–creatinine ratios of means for treatment group from ANCOVA model include adjusting for baseline measurement. All serum ratios of 
means for treatment group from mixed effects model include adjusting for baseline measurement and after treatment time. Interactions between treatment group and post treatment time were not statistically 
significant (p>0·050) so estimates are for overall post treatment differences. Outcome variables were log transformed and the treatment group difference back transformed–give a ratio. NTx=N-terminal cross-
linking telopeptide of type I collagen. PINP=procollagen type I N propeptide. CTx=C-terminal cross-linking telopeptide of type I collagen. 
Table 2: Biochemical markers of bone turnover at baseline, 13 weeks, and 26 weeks by treatment group  
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Dietary intake of vitamin D, calcium, and selenium 
assessed by 7-day diet diary were similar in all three 
treatment groups at baseline. Dietary selenium intake 
decreased between baseline and 26 weeks in all three groups 
but did not differ between groups at 26 weeks (appendix 
p 6). The safety assessments for diabetes and thyroid 
function did not differ between treatment groups. There was 
a small difference in glycated haemoglobin with treatment 
between 200 μg and placebo but this was not a clinically 
significant difference (appendix p 7). Seven (6%) of 
120 participants were withdrawn from treatment at week 13 
due to abnormal thyroid-stimulating hormone 
concentrations (one in the 200 μg group, three in the 50 μg 
group, and three in the placebo group) and one due to 
abnormal blood glucose (in the 50 μg group). The number 
and severity of adverse events, and the systems affected by 
adverse events were similar across treatment groups 
(appendix p 8). There were three serious adverse events: a 
Placebo Selenite 50 μg Selenite  200 μg Selenite 50 μg vs placebo Selenite 200 μg vs placebo Selenite 200 μg vs 50 μg
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Data are n, mean (95% CI), difference in means (95% CI), or p value. Difference in means for treatment group from linear mixed model adjusting for baseline measurement and post treatment time. Interactions 
between treatment group and post treatment time were not statistically significant (p>0·050) so estimates are for overall post treatment differences. 
Table 3: Serum selenium and selenoprotein P at 13 weeks and 26 weeks by treatment group
Placebo Selenite 50 μg Selenite 200 μg Selenite 50 μg vs placebo Selenite 200 μg vs placebo Selenite 200 μg vs 50 μg
n Mean n Mean n Mean Difference p value Difference p value Difference p value
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Data are n, mean (95% CI), difference in means (95% CI), or p value. Difference in means for treatment group from mixed effects model adjusting for baseline measurement and after treatment time. Interactions 
between treatment group and after treatment time were not statistically significant (p>0·050) so estimates are for overall after treatment differences. 
Table 4: Physical functions tests at baseline, 13 weeks, and 26 weeks by treatment group 
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non-ST elevation myocardial infarction at week 18 (in the 50 
μg group), a diagnosis of bowel cancer after routine 
population screening at week 2 (in the placebo group), and a 
pulmonary embolus due to metastatic bowel cancer at week 
4 (in the 200 μg group). All severe adverse events were 
judged by the principal investigator as unrelated to trial 
medication.
Analyses were repeated in the per-protocol group for all 
efficacy and safety endpoints, and the results did not 
differ from those in the primary analysis population.
Discussion
We did a well powered randomised, double-blind, 
placebo-controlled study of the effects of selenium 
supple mentation on musculoskeletal health in post-
menopausal women and found that supplemental 
selenite 200 μg or 50 μg daily increased serum selenium 
concentrations but had no effect on biochemical markers 
of bone turnover, BMD, or physical function. This result 
is key because, to our knowledge, our study is the first 
randomised controlled trial of selenium supplementation 
for musculoskeletal health. 
Serum selenium in the 200 μg treatment group 
increased from 80 μg/L to 105 μg/L. Mortality data 
suggest that the optimum range for serum selenium is 
120–150 μg/L. Although serum selenium did not reach 
this range, based on the cross-sectional correlation of 
serum selenium and NTx to creatinine ratio in our 
previous study,5 an increase of 30% in serum selenium 
should be enough to cause a change in bone markers. 
Biochemical markers of bone turnover are dynamic and 
respond to bone active agents within days. For example, 
bone markers are decreased by about 20% 2 weeks after 
starting calcium supplements.31 Selenium 200 μg daily 
has been shown to be effective in Graves’ eye disease23 
and cancer prevention studies;21 therefore there is good 
evidence that this dose is high enough to be biologically 
active in humans. Higher dose supplements might have 
an effect on bone; however, across the two doses that we 
have studied, there was no dose-response effect. Higher 
doses might also increase the risk of adverse effects.24 
Other forms of selenium supplementation might have 
different effects, but the common pathway is likely to be 
increased selenium availability.
There was a small difference in lumbar spine BMD 
between the 50 μg group and placebo, but in the absence 
of any effect on bone turnover or any BMD effect in the 
200 μg group, this is likely to be a spurious result. 
There are epidemiological, observational, and pre-
clinical data to suggest that higher selenium intake 
might have beneficial effects on musculoskeletal health. 
Higher selenium status is associated with higher BMD 
in men in the Netherlands.13 Higher dietary selenium 
intake is associated with lower hip fracture risk in older 
adults in the USA14 and higher BMD in middle-aged and 
older adults in Europe.5,13 Lower serum selenium and 
dietary selenium are associated with lower muscle mass 
and poorer muscle function in older adults.17 
The proposed mechanism of action of selenium to 
reduce reactive oxygen species via increased biosynthesis 
of selenoproteins, and so reduce the pro-resorptive drive 
to osteoclasts was plausible. However, despite increased 
serum selenoprotein P, we saw no effect on markers of 
bone resorption. It might be that selenium status is a 
marker for other factors acting on bone health, or that a 
single factor approach is ineffective and selenium is part 
of a more complex system. 
The population in this study was generally repre-
sentative of postmenopausal women in the UK in terms 
of body-mass index, BMD, vitamin D status, and calcium 
intake. Their dietary selenium intake at baseline was 
higher than expected for the UK, but at 26 weeks was 
more typical. 
We only studied women, and it is possible that the 
effects of selenium on bone would be different in men. 
However, postmenopausal women have higher bone 
resorption than men, and we hypothesised that selenium 
could act particularly through one of the resorption 
pathways activated by oestrogen deficiency. Therefore, in 
the absence of any effect in women, we do not think an 
effect in men is likely. These were healthy osteopenic 
women, and it is possible that selenium supplementation 
could have greater effect in women with underlying 
inflammatory disorders driving higher bone turnover. 
Our outcome measures are surrogates (BMD and bone 
turnover for fracture and physical function tests for falls), 
but they are well validated surrogates, and the absence of 
effect in our study suggests that further studies with fall 
and fracture endpoints are probably not justified in this 
patient group.
Other trials have shown benefit in cancer prevention; 
thus selenium might have benefits for human health. 
However, we conclude that sodium selenite supple-
mentation at these doses is unlikely to have beneficial 
effects on musculoskeletal health in postmenopausal 
women. 
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